JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis
- 24 June 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (9), 1185-1187
- https://doi.org/10.1093/ecco-jcc/jjaa074
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-AnalysisGastroenterology, 2020
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine ProgrammeJournal of Crohn's and Colitis, 2020
- JAK Inhibitors Safety in Ulcerative Colitis: Practical ImplicationsJournal of Crohn's and Colitis, 2020
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical TrialsClinical Gastroenterology and Hepatology, 2019
- JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?Gut, 2019
- Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2019
- Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic ReviewJournal of Crohn's and Colitis, 2019
- The safety of vedolizumab for ulcerative colitis and Crohn's diseaseGut, 2016
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS studyGut, 2015
- Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel diseasePharmacological Research, 2013